izpis_h1_title_alt

A machine learning-based risk stratification model for ventricular tachycardia and heart failure in hypertrophic cardiomyopathy
ID Smole, Tim (Author), ID Žunkovič, Bojan (Author), ID Pičulin, Matej (Author), ID Kokalj, Enja (Author), ID Robnik Šikonja, Marko (Author), ID Kukar, Matjaž (Author), ID Fotiadis, Dimitrios I. (Author), ID Pezoulas, Vasileios C. (Author), ID Tachos, Nikolaos S. (Author), ID Barlocco, Fausto (Author), ID Mazzarotto, Francesco (Author), ID Popović, Dejana (Author), ID Maier, Lars S. (Author), ID Velicki, Lazar (Author), ID MacGowan, Guy A. (Author), ID Olivotto, Iacopo (Author), ID Filipović, Nenad (Author), ID Jakovljević, Djordje G. (Author), ID Bosnić, Zoran (Author)

.pdfPDF - Presentation file, Download (4,11 MB)
MD5: C4B304E87AAF7747E4BC442E5DD5BC3A
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S001048252100442X This link opens in a new window

Abstract
Background: Machine learning (ML) and artificial intelligence are emerging as important components of precision medicine that enhance diagnosis and risk stratification. Risk stratification tools for hypertrophic cardiomyopathy (HCM) exist, but they are based on traditional statistical methods. The aim was to develop a novel machine learning risk stratification tool for the prediction of 5-year risk in HCM. The goal was to determine if its predictive accuracy is higher than the accuracy of the state-of-the-art tools. Method: Data from a total of 2302 patients were used. The data were comprised of demographic characteristics, genetic data, clinical investigations, medications, and disease-related events. Four classification models were applied to model the risk level, and their decisions were explained using the SHAP (SHapley Additive exPlanations) method. Unwanted cardiac events were defined as sustained ventricular tachycardia occurrence (VT), heart failure (HF), ICD activation, sudden cardiac death (SCD), cardiac death, and all-cause death. Results: The proposed machine learning approach outperformed the similar existing risk-stratification models for SCD, cardiac death, and all-cause death risk-stratification: it achieved higher AUC by 17%, 9%, and 1%, respectively. The boosted trees achieved the best performing AUC of 0.82. The resulting model most accurately predicts VT, HF, and ICD with AUCs of 0.90, 0.88, and 0.87, respectively. Conclusions: The proposed risk-stratification model demonstrates high accuracy in predicting events in patients with hypertrophic cardiomyopathy. The use of a machine-learning risk stratification model may improve patient management, clinical practice, and outcomes in general.

Language:English
Keywords:hypertrophic cardiomyopathy, risk stratification, machine learning, artificial intelligence
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FRI - Faculty of Computer and Information Science
Publication status:Published
Publication version:Version of Record
Year:2021
Number of pages:9 str.
Numbering:Vol. 135, art. 104648
PID:20.500.12556/RUL-138683 This link opens in a new window
UDC:004.8:616.12-008.46
ISSN on article:0010-4825
DOI:10.1016/j.compbiomed.2021.104648 This link opens in a new window
COBISS.SI-ID:71489795 This link opens in a new window
Publication date in RUL:09.08.2022
Views:540
Downloads:75
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Computers in biology and medicine
Shortened title:Comput. biol. med.
Publisher:Elsevier
ISSN:0010-4825
COBISS.SI-ID:189801 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:hipertrofična kardiomiopatija, napovedovanje tveganja, strojno učenje, umetna inteligenca

Projects

Funder:EC - European Commission
Funding programme:H2020
Project number:777204
Name:In silico trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy
Acronym:SILICOFCM

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back